Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relacorilant plus Enzalutamide in mCRPC
NCT03674814Phase 1Completed
- Sponsor
- University of Chicago
- Start
- Oct 2018
- Primary completion
- Jun 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of relacorilant in prostate cancer (PCa), sponsored by University of Chicago. Primary endpoints: Treatment-Related Adverse Events at 28 days and Change in steady-state (C-trough) enzalutamide caused by relacorilant at 28 days. Started Oct 2018; status: completed.
02
Drugs
relacorilant
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03674814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03674814.